.when his patients ask how long they’ll be at the hospital with a procedure like this, he tries to manage their expectations.
.
.
.
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
. taking ustekinumab�a biologic that targets a different aspect of the immune system," gelfand said.
.
richard lipton, md, director, montefiore headache center; edwin s. lowe professor and vice chairman of neurology, albert einstein college of medicine.
.
.